

Appendix K
UnitedHealth Group and Amedisys Redaction Log OHA Request for Information

Redaction	Document	Page and Paragraph Number	Information Redacted	Reason for Redaction	Statutory Basis
Preliminary Review Documents					
1	Appendix A	pg. 2, ¶12	UHG personnel and responsibilities	Non-public information that pertains to UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
2	Appendix A	pg. 2, ¶14	LHC patient counts and clinical staff counts in Oregon	Non-public information that pertains to UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
3	Appendix A	pg. 2, ¶15	The number of Refresh unique patient counts and number of employees in Oregon	Non-public information that pertains to UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
4	Appendix A	pg. 2, ¶16	The number of Optum Pharmacies unique patient counts and number of employees in Oregon	Non-public information that pertains to UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
5	Appendix A	pg. 3, ¶11	The number of Optum Care unique patient counts and number of employees in Oregon	Non-public information that pertains to UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
6	Appendix A	pg. 3, ¶12	The number of Optum Health Services for I-SNP/IE-SNPs unique patient counts and number of employees in Oregon	Non-public information that pertains to UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
7	Appendix A	pg. 3, ¶13	The number of SCA unique patient counts and number of employees in Oregon	Non-public information that pertains to UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
8	Appendix A	pg. 3, ¶14	The number of Landmark unique patient counts and number of employees in Oregon	Non-public information that pertains to UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
9	Appendix A	pg. 3, ¶15	The number of HouseCalls unique patient counts and number of employees in Oregon	Non-public information that pertains to UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
10	Appendix A	pg. 4, ¶11	The number of AbleTo unique patient counts and number of employees in Oregon	Non-public information that pertains to UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
11	Appendix A	pg. 4, ¶16	The number of Amedisys unique patient counts and number of employees in Oregon	Non-public information that pertains to Amedisys strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
12	Appendix C	pg. 1, ¶¶12-4	UHG and Amedisys geographic coverage, staffing, and patient capacity for Optum and Amedisys locations in Oregon	Non-public information that pertains to Amedisys and UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets

Appendix K
UnitedHealth Group and Amedisys Redaction Log OHA Request for Information

13	Appendix C	pg. 2, ¶¶1-5	UHG and Amedisys geographic coverage, staffing, and patient capacity for Optum and Amedisys locations in Oregon	Non-public information that pertains to Amedisys and UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
14	Appendix C	pg. 3, ¶¶1, 3-6	UHG and Amedisys geographic coverage, staffing, and patient capacity for Optum and Amedisys locations in Oregon	Non-public information that pertains to Amedisys and UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
15	Appendix C	pg. 4, ¶1	UHG and Amedisys geographic coverage, staffing, and patient capacity for Optum and Amedisys locations in Oregon	Non-public information that pertains to Amedisys and UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
16	Optum Oregon Entities - Individual NPIs (Partial Submission of 12-19-2023)	Entire Document	Competitively sensitive non-public information regarding the number of providers and the mix of specialties of providers by individual service line.	Non-public information that pertains to Amedisys and UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
17	2024.01.02 Email (Partial submission of 1-2-2024)	Purchase price information for UHG deals in Oregon	Competitively sensitive non-public information regarding the valuation UHG assigns to certain assets and the prices UHG has agreed to pay for those assets.	Non-public information that pertains to Amedisys and UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
18	2024.01.02 Email (Partial submission of 1-2-2024)	UHG deals that have been pursued but not completed	Competitively sensitive non-public information regarding targets that UHG has considered.	Non-public information that pertains to Amedisys and UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
19	AbleTo Induvial Provider NPIs (Partial submission of 1-2-2024)	Entire Document	Competitively sensitive non-public information regarding the number of providers and the mix of specialties of providers by individual service line.	Non-public information that pertains to Amedisys and UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
20	UHG and Amedisys Org Chart (Partial submission of 1-5-2024)	Entire Document	Competitively sensitive non-public information regarding the structuring of UHG subsidiaries	Non-public information that pertains to Amedisys and UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
21	Landmark and HouseCalls NPIs (Partial submission of 1-5-2024)	Entire Document	Competitively sensitive non-public information regarding the number of providers and the mix of specialties of providers by individual service line.	Non-public information that pertains to Amedisys and UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets

Appendix K
UnitedHealth Group and Amedisys Redaction Log OHA Request for Information

22	Amedisys Unique Patients Served (Partial submission of 1-5-2024)	Entire Document	Competitively sensitive non-public information pertaining to Amedisys service line capabilities.	Non-public information that pertains to Amedisys and could be used for business advantage	ORS 192.345(2) Trade secrets
23	Attachment 1 - M&A Lists (Partial submission of 1-31-2024)	All documents in folder	Competitively sensitive non-public information regarding targets that UHG and LHC considered, their business strategy, and valuations.	Non-public information that pertains to UHG'S strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
24	Attachment 2 - Pipeline Reports (Partial submission of 2-2-2024)	All documents in folder	Competitively sensitive non-public information regarding targets that UHG and LHC considered, their negotiation tactics, and valuations.	Non-public information that pertains to Amedisys and UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
25	Attachment 3 - Individual provider NPIs for OptumCare, Refresh, HouseCalls, I/E-SNP, Landmark, and AbleTo (Partial submission of 2-2-2024)	All documents in folder	Competitively sensitive non-public information regarding the number of providers and the mix of specialties of providers by individual service line.	Non-public information that pertains to Amedisys and UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
26	Appendix F-CONFIDENTIAL (Partial submission of 2-2-2024)	Item 3(b)	Competitively sensitive non-public information regarding acquisition target that UHG considered but did not complete	Non-public information that pertains to UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
27	Appendix F-CONFIDENTIAL (Partial submission of 2-2-2024)	Item 4 chart	Competitively sensitive non-public information regarding the number of unique members in Oregon by plan type.	Non-public information that pertains to UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
Comprehensive Review Documents					
1	Appendix A	All documents in folder		Contains competitively sensitive non-public information regarding UHG's submission to submit a bid for Amedisys.	ORS 192.345(2) Trade secrets.
2	Appendix A	Project Aurora Delegation Authority Pg. 9-16	Legally privileged information.	The redacted information contains legally privileged information.	Attorney-client privilege.
3	Appendix B	Entire document		Contains competitively sensitive non-public information regarding UHG's advisors and consultants.	ORS 192.345(2) Trade secrets.
4	Appendix C	All documents in folder		Contains competitively sensitive non-public information regarding UHG's budgets, quarterly reports, and annual reports.	ORS 192.345(2) Trade secrets.
5	Appendix D	All documents in folder		Contains competitively sensitive non-public information regarding UHG's advisors and consultants pro forma projections.	ORS 192.345(2) Trade secrets.
6	Appendix E	Entire document		Contains list of non-public investigations.	ORS 192.345(2) Trade secrets.
7	Appendix F	All documents in folder		Contains UHG's non-public and competitively sensitive plans for divestiture.	ORS 192.345(2) Trade secrets.

Appendix K
UnitedHealth Group and Amedisys Redaction Log OHA Request for Information

8	Appendix G	Entire document		List of competitively sensitive non-public information regarding names and addresses of SNF residents who have received services from OHSI since 2019.	ORS 192.345(2) Trade secrets.
9	Appendix I	Entire Workbook		Confidential non-public information regarding Amedisys' payment history, patient volumes and demographics, and staffing.	ORS 192.345(2) Trade secrets.
10	United Response re UHG-Amedisys Requests	Pg. 31, item 5	Confidential information pertaining to Amedisys' budget.	Competitively sensitive non-public information regarding Amedisys' budget.	ORS 192.345(2) Trade secrets.
11	United Response re UHG-Amedisys Requests	Pg. 32, item 8	Confidential information pertaining to UHG divestiture plans.	Competitively sensitive non-public information regarding UHG divestiture plans.	ORS 192.345(2) Trade secrets.
12	United Response re UHG-Amedisys Requests	Pg. 36, item 16	Confidential information pertaining to UHG's rationale for the transaction.	Competitively sensitive non-public information regarding UHG deal rationale.	ORS 192.345(2) Trade secrets.
13	United Response re UHG-Amedisys Requests	Pg. 37, item 17	Information pertaining to confidential documents used to respond to item 16.	Competitively sensitive non-public information regarding UHG deal rationale.	ORS 192.345(2) Trade secrets.
14	United Response re UHG-Amedisys Requests	Pg. 53, item 22	Non-public information regarding LHC and Amedisys' capacity to serve patients in 2023.	Competitively sensitive non-public information regarding capacity.	ORS 192.345(2) Trade secrets.
15	Exhibit 38	Entire Folder	Non-public information regarding LHC contract negotiations	Competitively sensitive non-public information regarding negotiation and rates	ORS 192.345(2) Trade secrets.
16	Exhibit 42	Entire Folder	Non-public information regarding LHC's future business plans and strategy.	Competitively sensitive non-public information regarding LHC business strategy.	ORS 192.345(2) Trade secrets.
17	Exhibit 43	Entire Folder	Non-public information regarding LHC's internal policies.	Competitively sensitive information regarding LHC's staffing policies and practices.	ORS 192.345(2) Trade secrets.
18	Exhibit 44	Entire Folder	Non-public information regarding acquired entities.	Competitively sensitive information regarding staffing, contracts, and patients served.	ORS 192.345(2) Trade secrets.
19	Exhibit 57	Entire Folder	Non-public information regarding insurance contracts.	Competitively sensitive information regarding terminated insurance contracts.	ORS 192.345(2) Trade secrets.
20	Exhibit 58	Entire Folder	Non-public information regarding compensation structure.	Competitively sensitive information regarding Oregon Medical Group compensation structure and benefits.	ORS 192.345(2) Trade secrets.
21	Exhibit 60	Entire Folder	Non-public information regarding divestiture agreement.	Competitively sensitive copy of the Divestiture Agreement.	ORS 192.345(2) Trade secrets.
22	Exhibit 67	Entire Folder	Non-public information regarding Optum Care Network policies.	Competitively sensitive copy of the Optum Care Network Provider Manual.	ORS 192.345(2) Trade secrets.
23	Exhibit 68	Entire Folder	Non-public information regarding Optum Care Network policies.	Competitively sensitive copy of an Optum Care Network Management Services Agreement.	ORS 192.345(2) Trade secrets.

Appendix K
UnitedHealth Group and Amedisys Redaction Log OHA Request for Information

24	United Response to 7.11.2024 Requests for Additional Information	Pg. 1, item 23	Non-public information regarding divestiture plans.	Competitively sensitive and confidential presentation sent to the Department of Justice regarding divestiture plans.	ORS 192.345(2) Trade secrets.
25	United Response to 7.11.2024 Requests for Additional Information	Pg. 2, item 24	Non-public information regarding UHG and Amedisys integration plans.	Competitively sensitive information regarding UHG's benefits packages.	ORS 192.345(2) Trade secrets.
26	United Response to 7.11.2024 Requests for Additional Information	Pg.3, item 25	Non-public information regarding divestiture plans.	Competitively sensitive and confidential information regarding the Amedisys Disclosure Letter to Agreement and Plan of Merger.	ORS 192.345(2) Trade secrets.
27	United Response to 7.11.2024 Requests for Additional Information	Pg. 3, item 26	Non-public information UHG and Amedisys integration plans.	Competitively sensitive information pertaining to confidential materials for UHG and Amedisys' integration plans.	ORS 192.345(2) Trade secrets.
28	United Response to 7.11.2024 Requests for Additional Information	Pg. 4-6, item 29-32	Non-public information UHG and Amedisys integration plans.	Competitively sensitive information pertaining to confidential materials for UHG and Amedisys' integration plans.	ORS 192.345(2) Trade secrets.
29	United Response to 7.11.2024 Requests for Additional Information	Pg. 7, item 34	Non-public information regarding supplier contracts.	Competitively sensitive information regarding supplier pricing practices.	ORS 192.345(2) Trade secrets.
30	United Response to 7.11.2024 Requests for Additional Information	Pg. 24-25, item 43	Non-public information regarding compensation.	Competitively sensitive information regarding mileage reimbursement practices.	ORS 192.345(2) Trade secrets.
31	United Response to 7.11.2024 Requests for Additional Information	Pg. 26, item 45	Non-public information regarding UHG business strategy.	Competitively sensitive information regarding UHG acquisition evaluations.	ORS 192.345(2) Trade secrets.
32	United Response to 7.11.2024 Requests for Additional Information	Pg. 26, item 46	Non-public information regarding UHG business strategy.	Competitively sensitive information regarding UHG acquisition evaluations.	ORS 192.345(2) Trade secrets.
33	United Response to 7.11.2024 Requests for Additional Information	Pg. 27, item 47	Non-public information regarding UHG business strategy.	Competitively sensitive information regarding UHG acquisition evaluations.	ORS 192.345(2) Trade secrets.
34	United Response to 7.11.2024 Requests for Additional Information	Pg. 28, item 50	Non-public information regarding UHG business strategy.	Competitively sensitive information regarding UHG acquisition evaluations.	ORS 192.345(2) Trade secrets.
35	United Response to 7.11.2024 Requests for Additional Information	Pg. 35-36, item 59	Non-public information regarding UHG employment contracts.	Competitively sensitive information regarding UHG employment agreements.	ORS 192.345(2) Trade secrets.
36	United Response to 7.11.2024 Requests for Additional Information	Pg. 38, item 63	Non-public information regarding UHC commercial contracts.	Competitively sensitive information regarding number of UHC commercial contracts.	ORS 192.345(2) Trade secrets.
37	United Response to 10.02.2024 Clarifying Questions	Pg.1 item1-3	Non-public information regarding staffing.	Competitively sensitive information regarding Optum staffing.	ORS 192.345(2) Trade secrets.
38	United Response to 10.02.2024 Clarifying Questions	Pg.1-2 item 2	Non-public information regarding staffing.	Competitively sensitive information regarding LHC staffing.	ORS 192.345(2) Trade secrets.
39	United Response to 10.02.2024 Clarifying Questions	Pg. 2 item 3	Non-public information regarding staffing.	Competitively sensitive information regarding LHC employee benefits.	ORS 192.345(2) Trade secrets.
40	United Response to 10.02.2024 Clarifying Questions	Pg. 3 item 4	Non-public information regarding UHG contracts.	Competitively sensitive information regarding UHG contract negotiations.	ORS 192.345(2) Trade secrets.
41	Exhibit 69	Entire Document	Non-public information regarding Optum policies.	Competitively sensitive information regarding Optum employee policies.	ORS 192.345(2) Trade secrets.